* Enters into a global collaboration to develop and
commercialize Novel BET inhibitors developed by Jubilant Biosys
for the treatment of hematological malignancies
The post BRIEF-TG Therapeutics enters into collaboration to develop and commercialize Novel BET inhibitors appeared first on NASDAQ.